Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
What Dr. files
- Others100
- Updates54
- Investor Meet51
- Important41
- Board Meeting9
- PPTs6
Dr. Reddy's Laboratories Limited has informed the Exchange about Allotment of Employee Stock options
Dr. Reddy's has announced its 42nd Annual General Meeting on July 23. A final dividend of ₹8 per equity share for FY 2025-26 was declared, with a record date of July 10 and payment by July 30.
DRL greening operations: Net Zero target by FY2045 (SBTi approved), 78% renewable power in FY26, and all primary boilers are now coal-free. Scope 3 emissions reduced by 7.7%. The company launched a generic semaglutide in India and invested ₹111.41 Cr in CSR, impacting over 1.1 million people. No major regulatory...
Dr. Reddy's allotted 6,730 equity shares to employees exercising stock options. This increases the total issued share capital to Rs. 83.47 Cr. The new shares were issued at various exercise prices.
Dr. Reddy's secured Health Canada approval for its generic Semaglutide Injection, becoming the first to get market authorization in Canada. This enables commercialization of this key diabetes treatment in the world's second-largest Semaglutide market, showcasing Dr. Reddy's complex generics expertise.